Mirvaso (Brimonidine Tartrate)

Brimonidine is a selective alpha‑2 adrenergic receptor agonist. When applied to the skin, it activates these receptors on the smooth muscle of superficial blood vessels, causing vasoconstriction. This reduces blood flow to the area and diminishes the redness characteristic of rosacea.

The dosing regimen for Mirvaso is determined by the prescribing clinician. Typically, a thin layer is applied once daily to the affected facial areas, but the exact amount and frequency should follow the healthcare professional’s instructions.

Safety data for Mirvaso in pregnancy and lactation are limited. The product’s pregnancy category is not established, so it should only be used if the potential benefit justifies any potential risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician.

To request Mirvaso, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirvaso’s primary advantage is its rapid vasoconstrictive action, which can improve facial redness within hours. Unlike oral antibiotics or retinoids that target inflammation, brimonidine directly reduces blood flow. It is generally used when persistent erythema is the dominant symptom, whereas other agents may be chosen for papules or pustules.

Mirvaso gel should be stored at room temperature, below 25 °C, in its original container. Keep the tube tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Do not use the product if the gel appears discoloured or the packaging is damaged.

Apply a thin layer of Mirvaso gel to clean, dry facial skin once daily, preferably in the morning. Use only the amount needed to cover the affected areas and avoid contact with eyes, mouth and broken skin. Wash hands after application.

Serious risks, though rare, include severe allergic reactions such as contact dermatitis, systemic hypotension leading to dizziness or fainting, and skin ulceration at the application site. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, or significant skin changes.

Mirvaso should not be used by individuals with known hypersensitivity to brimonidine tartrate or any component of the gel. It is also contraindicated on broken or irritated skin, and caution is advised for patients with cardiovascular conditions that could be worsened by vasoconstriction.